Evidence map›Paper›PMID 41977128›Full record

ArticleInternational journal of molecular sciences2026

Identification of Actionable Gene Variants in Pulmonary Large-Cell Neuroendocrine Carcinoma: A Real-World Analysis of a Polish Cohort.

Adam Szpechcinski, Magdalena Pelc, Urszula Lechowicz, Malgorzata Szolkowska, Joanna Moes-Sosnowska, Piotr Rudzinski, Emil Wojda, Paulina Skronska, Elzbieta Podgorska, Krystyna Maszkowska-Kopij and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Adam SzpechcinskiDepartment of Genetics and Clinical Immunology, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.ORCID 0000-0002-8920-6931
Magdalena PelcDepartment of Genetics and Clinical Immunology, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.ORCID 0000-0003-4475-9003
Urszula LechowiczDepartment of Genetics and Clinical Immunology, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.ORCID 0000-0002-2645-8779
Malgorzata SzolkowskaDepartment of Pathology, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Joanna Moes-SosnowskaDepartment of Genetics and Clinical Immunology, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.ORCID 0000-0003-1706-8290
Piotr RudzinskiClinical Department of Thoracic Surgery, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Emil WojdaClinical Department of Thoracic Tumors, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Paulina SkronskaDepartment of Genetics and Clinical Immunology, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Elzbieta PodgorskaDepartment of Genetics and Clinical Immunology, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.ORCID 0000-0003-0405-9299
Krystyna Maszkowska-KopijOutpatient Clinic, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Mateusz PolaczekClinical Department of Thoracic Tumors, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.ORCID 0000-0003-2737-1808
Tadeusz OrlowskiClinical Department of Thoracic Surgery, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Renata LangfortDepartment of Pathology, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Joanna Chorostowska-WynimkoDepartment of Genetics and Clinical Immunology, The Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.ORCID 0000-0003-1743-2961

Funding

Institute of Tuberculosis and Lung Diseases in Warsaw, Poland statutory research activity projects no. 3.3/2022, 3.11/2023, and 3.13/2025
6 · The paper itself

Abstract

Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare lung malignancy characterized by an aggressive clinical course and an unfavorable prognosis. Next-generation sequencing (NGS) has revealed that LCNECs exhibit molecular features resembling either small-cell lung carcinoma (SCLC-like LCNEC) or non-small cell lung carcinoma (NSCLC-like LCNEC). This study aimed to characterize the incidence of actionable gene variants in a retrospective cohort of LCNEC patients using a targeted NGS approach. Microscopic diagnosis was established according to the 2021 World Health Organization (WHO) classification using a standard immunohistochemical (IHC) panel. In total, 216 LCNEC tumor samples were analyzed for molecular variants in 17 genes using the RNA-based Archer FusionPlex Lung NGS assay (Integrated DNA Technologies, USA) and the MiSeq platform (Illumina, USA)-an algorithm utilized for routine NSCLC diagnosis. Overall, 46 variants were identified in 46/216 (21.3%) tumor samples, with 28/216 (13%) LCNECs harboring at least one actionable molecular variant potentially targetable by registered or investigational agents.

Indexed as

Carcinoma, Large CellCarcinoma, NeuroendocrineLung NeoplasmsAdultAgedAged, 80 and overFemaleGenetic VariationHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationPolandRetrospective Studiesgene fusion variantnext-generation sequencing (NGS)pulmonary large-cell neuroendocrine carcinoma (LCNEC)single nucleotide variant (SNV)targeted therapy

Identifiers

PMID41977128
PMCPMC13073004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.